+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating if adding a specific type of radiation called stereotactic body radiation therapy SBRT before chemoimmunotherapy and surgery is effective for people with borderline resectable non-small cell lung cancer NSCLC. This study focuses on patients who may be able to have surgery and aims to assess the tolerability and effects of combining these treatments. The research is sponsored by the University of Maryland, Baltimore.

Age: 18Years +All GendersPhase 1
4 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
R

Actively Recruiting

Researchers are evaluating the antidepressant effects of ALTO-100 compared to a placebo in adults with Bipolar Disorder I or II who are currently experiencing a major depressive episode. This study aims to understand how patient characteristics may influence treatment outcomes when ALTO-100 is used along with a mood stabilizer andor an atypical antipsychotic. The trial also focuses on assessing safety, tolerability, and efficacy during a later open-label treatment phase. Participants in the study will be randomly assigned to receive either ALTO-100 at a dose of 40 mg twice daily or a matching placebo for 6 weeks during the double-blind treatment period. Those who qualify and continue will enter an open-label period lasting up to 7 weeks, where all will receive ALTO-100 40 mg twice daily. The study uses a quadruple-blind design to ensure unbiased results. During the trial, participants will undergo regular assessments of depression symptoms using scales such as the Montgomery-sberg Depression Rating Scale MADRS, Patient Health Questionnaire PHQ-9, and Clinician Global Impression Scale-severity CGI-S. Safety monitoring includes tracking adverse events, heart rate, blood pressure, weight, and suicidality over a total period of up to 13 weeks. The study evaluates changes from baseline to week 6 during the double-blind phase and continues safety assessments through the open-label period.

Age: 18Years - 70YearsAll GendersPhase 2
68 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
R

Actively Recruiting

This study focuses on adults in the United States with schizophrenia who are prescribed xanomeline and trospium chloride XT therapy. It aims to understand patients treatment preferences and satisfaction with this medication combination. The research is observational and tracks real-world experiences rather than testing new treatments. Participants receive xanomeline and trospium chloride therapy according to the product label. The study observes how patients use this treatment and collects information about dosing and any changes over time. Data is gathered at multiple points, including baseline, Month 1, Month 3, and Month 6, to monitor treatment plans and medication adjustments. During the study, participants provide information through questionnaires about their medication preferences and satisfaction. Researchers also collect clinical and demographic data, track treatment plans, dose changes, and reasons for discontinuing therapy. This information helps assess the real-world use and patient experience with XT therapy over approximately six months.

Age: 18Years +All Genders
20 locations
P

Actively Recruiting

Researchers are studying early-stage breast cancer treatment by evaluating a new approach using the GammaPod machine, which is FDA approved to deliver focused radiation specifically to the breast. This technology aims to target radiation precisely to the tumor area, reducing exposure to nearby healthy tissues. The study focuses on delivering radiation before surgery, which has shown improved disease-free survival in some cancers, and seeks to find a safe and effective radiation dose while assessing skin changes and quality of life after treatment. Participants will receive one of four different dose levels of preoperative radiation therapy to the partial breast using the GammaPod device. This treatment is given before the lumpectomy surgery, which removes the tumor. The study is a dose-escalation phase Ib trial, with dose levels ranging from 21 Gy to 30 Gy delivered in a single fraction. Each participants breast is held securely in place by a breast cup system during treatment for precise targeting. During the study, participants will be closely monitored for dose-limiting toxicities and safety outcomes over five years. Researchers will assess radiation-related skin changes using questionnaires from patients and physicians and photo software analysis tools. Other evaluations include tumor response, local tumor recurrence, and quality of life measures. The study involves imaging with CT and MRI scans and requires participants to lie prone for treatment. The total follow-up duration is five years to determine the maximum tolerated dose and safety profile of this radiation approach.

Age: 45Years +FEMALEPhase Not Applicable
4 locations

1-10 of 30

1